Promising IP is recognized too late—or never
Commercialization teams see what is formally disclosed. The earliest evidence of an invention often lives elsewhere.
THE GOVERNED RESEARCH OPERATING SYSTEM
Every discovery deserves a path out of the lab.
AMOS Bio connects research data, teams, tools, and institutional systems so AI can uncover promising IP, form better collaborations, and run continuous discovery loops—with evidence and human control at every step.
Built on AMOSModel independentHuman governedEvidence backed
ILLUSTRATIVE PROGRAMCONTINUOUS
SIGNAL
Potential invention surfaced
A recurring method improvement appears across experiment notes, a preprint draft, and assay results.
3 supporting sources1 open question
evidence assembled
NEXT BEST ACTION
Review before public disclosure
AMOS Bio prepared the evidence, relevant prior art, inventor context, and recommended review path.
Human approval required
$117.7BU.S. academic R&D in FY2024
Risinginvention disclosures
Decliningtechnology-transfer staffing
The research is expanding. The human capacity to evaluate and move it is not.
THE CONTINUITY GAP
The problem is not a lack of research. It is everything that gets lost between discovery and impact.
Valuable signals remain scattered across notebooks, inboxes, repositories, departments, and specialized systems. Research teams move quickly; institutional memory does not.
Collaborators cannot see the capability next door
A method, model, dataset, instrument, or disease insight in one lab could unlock another program without either team knowing.
AI can analyze a task but cannot steward a program
Models lose context, switch tools, and produce findings without a durable record of evidence, authority, or what happened next.
ONE INSTITUTION · THREE COMPOUNDING ENGINES
Build the research system once. Let every discovery strengthen it.
01
Commercialization intelligence
Continuously assemble the evidence around discoveries, identify potential inventions earlier, prioritize portfolios, find commercial partners, and prepare the next action for human approval.
02
Institutional collaboration graph
Connect public research, grants, methods, equipment, expertise, and permissioned institutional data to reveal collaborations that organizational silos routinely hide.
03
Governed discovery loops
Set a scientific objective. AMOS Bio forms hypotheses, invokes approved tools, measures evidence, proposes experiments, and learns from every result—inside explicit budgets and authority.
THE AUTONOMOUS DISCOVERY LOOP
Set the scientific goal. Keep the judgment human.
AMOS Bio can continuously gather evidence, form hypotheses, run approved computational tools, compare predicted and observed results, and propose the next experiment. It never turns a model’s confidence into institutional authority.
See how governance worksGOVERNEDLEARNEvery result updates the next action
01ObserveData · literature · results
02HypothesizeMechanism · target · candidate
03EvaluateModels · simulations · evidence
04ProposeExperiment · cost · success criteria
05MeasureObserved result · uncertainty
FROM SIGNAL TO TRANSLATION
One evidence chain. Different teams, shared continuity.
AMOS Bio does not replace scientific expertise, existing research systems, or commercialization judgment. It connects them into a governed operating model.
Technology commercialization
Give every disclosed invention a continuously updated evidence base, market map, partner pipeline, and governed action plan.
Research leadership
See institutional capability as a connected system and direct attention toward high-value programs, shared infrastructure, and collaboration opportunities.
Principal investigators and labs
Reduce the operational burden around discovery while preserving scientific authorship, private work, and final human judgment.
Biotech, pharma, and foundations
Run repeatable computational programs across bioinformatics, target discovery, repurposing, and experimental validation without losing provenance.
GOVERNANCE IS THE PRODUCT
Autonomy without scientific amnesia.
Every program retains the data, evidence, models, parameters, decisions, approvals, and outcomes that produced its current state. The research history survives any single model or conversation.
01
Data access stays scoped to the institution, team, and user.
02
Consequential actions wait for the right human authority.
03
Every analysis records sources, models, parameters, and uncertainty.
04
Every decision and action leaves a plain-language receipt.
05
The institution can change models without rebuilding its research system.
THE DESIGN-PARTNER PROGRAM
Start with commercialization. Prove value before changing lab behavior.
Begin with the systems already in use
Invention disclosures, documents, email, grants, publications, patent records, CRM and licensing systems—without asking every lab to adopt a new notebook.
Reconstruct a historical portfolio
Evaluate 25–100 prior disclosures against known outcomes to test whether the system identifies overlooked partners, risks, or opportunities.
Move a live portfolio into governed action
Start read-only, establish decision rules, then allow AMOS Bio to prepare bounded actions and park consequential work for approval.
Measure what matters
Time to initial assessmentQualified partner leadsDormant assets reactivatedWorkload per portfolio manager
DESIGN A BIO OPERATING SPRINT
Bring us the research bottleneck. We will map the fastest credible proof.
Start with one portfolio, collaboration problem, or discovery objective. You do not need a finished data strategy or a wholesale platform migration.
WHAT HAPPENS NEXT
- 01We review the objective, evidence, and authority boundaries.
- 02We respond with the right people and next step.
- 03If there is a fit, we scope a bounded design partnership.
This intake runs on AMOS. Your submission becomes an attributed CRM record, enters our governed company workflow, and leaves proof—using the same operating layer we deploy for research organizations.
BUILD THE NEXT RESEARCH SYSTEM WITH US
Give every invention a team that never stops learning.
We are selecting research institutions and life-sciences organizations for the first AMOS Bio design partnerships.
Start the conversation